What's the purpose of this trial?
Some blood, bone marrow, and lymphatic (hematologic) cancers such as Hodgkin/Non-Hodgkin lymphomas, chronic lymphocytic leukemia, and multiple myeloma, are over-represented in Veterans due to exposures including Agent Orange and an increased percentage of patients of African American ethnicity. Hematologic transplantation (HCT) is a common treatment for these cancers, but often leads to deconditioning, fatigue, muscle atrophy, and poor quality of life, which are associated with complications such as hospitalization and infection. Despite the significance of these symptoms, there are no approved treatments to prevent/reverse these long-term effects. The cancer itself, side effects of chemotherapy, and sedentary behavior, contribute to these effects. Although exercise before and after HCT has helped reduce these effects, it is inconsistently recommended to patients and most remain sedentary through and after treatment. The investigators are testing an alternative exercise strategy, neuromuscular electrical stimulation, to maintain physical function quality of life after HCT.
This trial is currently open and accepting patients.
What will happen during the trial?
You may be able to join this trial if you:
The following criteria is a partial list of reasons why patients may be
eligible to participate in this clinical trial. Further evaluation with a medical professional is
required.
Inclusion Criteria:
* adequate cognitive and language ability to provide consent
* Veteran enrolled in MTU at VAPSHCS for planned standard of care autologous HCT
Exclusion Criteria:
* active deep vein thrombosis or thrombophlebitis
* untreated hemorrhagic disorders
* concomitant study inclusion in other nutritional or physical exercise interventional trials
* concomitant use of anabolic agents
* rhabdomyolysis or other muscle conditions where NMES is contraindicated
* implanted cardiac device
* baseline patient-reported muscle soreness of 5-6 on the soreness likert scale that is unrelated to recent physical exertion
* history of prior hematologic stem cell transplant
* probable or definitive liver cirrhosis
* reduced renal clearance defined as Stage 4 chronic kidney disease (glomerular filtration rate \<45 ml/min/1.73 m2)
Additional Trial Information
Enrollment: 46 patients (estimated)
View More
